X

Drug Profile

Cenegermin - Dompe Farmaceutici

Alternative Names: Cenegermin-bkbj; Nerve growth factor - Anabasis/Dompe; Ophtha-NGF; Ophtha-NGF Intravitreal; Oxervate; rhNGF; Sentinel

Latest Information Update: 17 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Anabasis Pharma
Developer Dompe Farmaceutici; Ospedale San Raffaele
Class Anti-inflammatories; Antiglaucomas; Eye disorder therapies; Nerve growth factors; Neuroprotectants; Proteins
Mechanism of Action Nerve growth factor receptor agonists; Neuron stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Keratitis; Retinitis pigmentosa
New Molecular Entity Yes

Highest Development Phases

Marketed Keratitis
Phase III Dry eyes
Phase II Glaucoma; Retinitis pigmentosa
Phase I Eye disorders

Most Recent Events

04 Dec 2024 Dompe Farmaceutici completes a phase II trial for Dry eyes in Italy and USA (Ophthalmic) (NCT06244316)
22 Jan 2024 Dompe Farmaceutici initiates a phase II trial for Dry eyes in Italy and USA (Ophthalmic) (NCT06244316)
13 Mar 2023 Phase-I clinical trials in Eye disorders in Italy (Intravitreous) before 2023 (Dompe-Farmaceutici pipeline, March 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Latest webinar now available!

Our latest webinar, Navigating the Complex Landscape of Clinical Trials: Trends, Global Impact, including Hits & Misses 2024, is available now. Key topics include an analysis of trials with both positive and negative outcomes, failed trials of 2024, and impactful trials of 2024 that contributed to regulatory approvals or company revenue, followed by an outlook on a few pivotal trials to watch in 2025.